GE HealthCare Technologies Inc. filed a Form 8-K to provide recast unaudited historical financial information reflecting a change in reportable segments announced in the second quarter of 2026. The company combined its Imaging and Advanced Visualization Solutions businesses into a new operating segment, Advanced Imaging Solutions (AIS). GE HealthCare now reports three segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS). Total revenues for the first quarter ended March 31, 2026, were $5.1 billion, with AIS contributing $3.64 billion, PDx $770 million, and PCS $704 million. Segment EBIT was $479 million for AIS, $197 million for PDx, and $10 million for PCS. The filing includes supplemental financial data to aid comparability but has no impact on previously reported consolidated financial statements. GE HealthCare Technologies Inc. operates in the medical technology industry, providing diagnostic imaging, pharmaceutical diagnostics, and patient care solutions.

GE HealthCare Technologies Inc. reported second quarter 2026 financial results on July 29, 2026. Total revenue increased 5.7% to $5.3 billion, driven by Pharmaceutical Diagnostics and Advanced Imaging Solutions, while Patient Care Solutions declined 13.3%. Diluted earnings per share rose 16.5% to $1.24, supported by a net income of $561 million and tariff refunds totaling $129 million. The company recorded record organic order growth of 11.1%, resulting in a book-to-bill ratio of 1.15 times and a backlog of $23.9 billion. GE HealthCare reaffirmed its full-year 2026 guidance, including adjusted EPS between $4.80 and $5.00. The company operates in the medical technology industry, designing and manufacturing diagnostic imaging systems, patient monitoring solutions, and pharmaceutical diagnostics.

GE HealthCare Technologies Inc. announced a CFO transition, with Jay Saccaro resigning as CFO effective August 14, 2026, and George Newcomb appointed as interim CFO. The company also reported preliminary second quarter 2026 results, projecting a 5.7% year-over-year revenue growth to $5.295 billion and 3.5% organic revenue growth. GE HealthCare is a global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions.

GE HealthCare Technologies Inc. appointed Kevin A. Lobo to its Board of Directors and the Talent, Culture, and Compensation Committee, effective March 13, 2026. Additionally, directors Risa Lavizzo-Mourey and Tomislav Mihaljevic announced they will not stand for re-election at the company's 2026 Annual Meeting of Stockholders.